In recent years, increase in occurrence of fluoroquinolone (FQ)-resistant Salmonella Typhi isolates has caused considerable inconvenience in selecting appropriate antimicrobials for treatment of typhoid. The World Health Organization (WHO) recommends azithromycin for the empirical treatment option of uncomplicated typhoid. The CLSI updated the breakpoints of disc diffusion (DD) and MIC results of FQs and azithromycin for Salmonella Typhi in 2015, but DD breakpoints of ofloxacin and levofloxacin were not included. In this study, the inhibition zone diameters and MICs of nalidixic acid, ciprofloxacin, ofloxacin, levofloxacin and azithromycin were determined in Salmonella Typhi Kolkata isolates (n=146) over a 16-year period (1998 to 2013) and the data were compared with the available CLSI breakpoints. Very major error and major error (ME) of FQs were not observed in the study isolates, but the minor error of ciprofloxacin (15.8 %) and ME of azithromycin (3.5 %) exceeded the acceptable limit. A positive correlation between MICs of FQ and mutations in the quinolone-resistance-determining region (QRDR) showed the reliability of MIC results to determine FQ susceptibility of Salmonella Typhi (n=74). Isolates showing decreased ciprofloxacin susceptibility (MIC 0.125-0.5 µg ml À1 ) were likely to have at least one mutation in the QRDR region. 
INTRODUCTION
Typhoid fever, caused by Salmonella enterica serovar Typhi, remains a global public health problem especially in developing countries. Early administration of appropriate antimicrobials remains the mainstay for typhoid treatment. In untreated cases mortality may become as high as 30 %, which falls to <1 % with antimicrobial therapy (Cooke & Wain, 2004) . However, indiscriminate use of first-line antimicrobials such as ampicillin, chloramphenicol and co-trimoxazole has led to the worldwide emergence of multidrug-resistant (MDR) Salmonella Typhi (Rowe et al., 1997) . As a consequence, a fluoroquinolone (FQ) or ceftriaxone has been recommended by the World Health Organization (WHO) for treatment of uncomplicated typhoid, whether caused by MDR or pan-susceptible isolates (WHO, 2003) . The orally administered FQs, such as ciprofloxacin, ofloxacin and levofloxacin, are often preferred to parenteral ceftriaxone because those are less costly and easier to administer. However, treatment failure cases with ciprofloxacin have been reported from developing countries due to emergence of Salmonella Typhi with decreased ciprofloxacin susceptibility (DCS; MIC of ciprofloxacin 0.125-0.5 µg ml À1 ) (Chau et al., 2007; Parry et al., 2010; Vlieghe et al., 2012; Rahman et al., 2014) . In recent years, emergence of ciprofloxacin-resistant Salmonella Typhi isolates has become a growing concern in South and Southeast Asia (Menezes et al., 2011; Chiou et al., 2014) . Azithromycin has been shown to be an effective alternative to FQs for treatment of uncomplicated typhoid in several clinical trials (Effa & Bukirwa, 2008) . Of late, reports on sporadic occurrence of azithromycin-resistant Salmonella Typhi isolates pose a problem for selecting suitable antimicrobials for treatment of typhoid (Rai et al., 2012; Hassing et al., 2014) .
FQ resistance in Salmonella Typhi can be attributed to mutations in the quinolone-resistance-determining regions (QRDRs) of topoisomerase genes or acquisition of plasmidmediated quinolone resistance (PMQR) genes (Chau et al., 2007; Geetha et al., 2014) .
The Clinical and Laboratory Standards Institute (CLSI) has revised the MIC breakpoints of ciprofloxacin, ofloxacin and levofloxacin and the disc diffusion (DD) breakpoints of ciprofloxacin for Salmonella species (CLSI, 2015) . But, no levofloxacin or ofloxacin DD breakpoints for Salmonella have been documented by the CLSI. The DD and MIC breakpoints of azithromycin for Salmonella Typhi have been incorporated in the CLSI (2015) document. It was observed that the MIC breakpoint result of any antimicrobial is confirmatory to designate any organism as susceptible (S), intermediate (I) or resistant (R) (Andrews, 2001) . Since determination of MIC breakpoint needs additional logistics and requires extra time for performing the test, determination of DD breakpoint is a convenient method to report the antimicrobial susceptibility of Salmonella Typhi.
In this study, we determined the inhibition zone diameters and MICs of nalidixic acid, ciprofloxacin, ofloxacin, levofloxacin and azithromycin for Salmonella Typhi isolates from Kolkata, India, collected over a period of 16 years (1998 to 2013) followed by evaluation of the breakpoints of the aforementioned antimicrobials as included in the document by CLSI (2015) . The changing trend of ciprofloxacin susceptibility of the isolates over the years is reported. The mechanism of FQ resistance was determined and correlated with the FQ susceptibility results of Salmonella Typhi.
METHODS
Bacterial isolates. Salmonella Typhi isolates (n=146) used in this study were isolated and stored at À70 C in brain/heart infusion broth (BD, Sparks, MD, USA) with 15 % glycerol (v/v) in the Gastrointestinal Tract Pathogens Repository (GTPR) at the National Institute of Cholera and Enteric Diseases (NICED), Kolkata, India, during 1998À2013. The isolates were revived and further confirmed before the study by biochemical testing following standard protocols (WHO, 1983) and serotyping using Salmonella poly-and monovalent antisera (Denka Seiken).
Antimicrobial susceptibility testing. Antimicrobial susceptibility testing was performed by the Kirby-Bauer DD method on MuellerHinton agar (BD) as described in the CLSI guidelines using the following antimicrobial discs: nalidixic acid (30 µg), ciprofloxacin (5 µg), ofloxacin (5 µg), levofloxacin (5 µg) and azithromycin (15 µg) (BD) (CLSI, 2012) . The MICs of nalidixic acid, ciprofloxacin, ofloxacin, levofloxacin and azithromycin were determined by Etest according to the manufacturer's instructions (AB Biodisk). Escherichia coli ATCC 25922 was used as control strain. Interpretation was done following the CLSI guidelines (CLSI, 2015) , except for DD breakpoints of ofloxacin and levofloxacin (Sjolund-Karlsson et al., 2015) ( Table 1) .
Determination of molecular mechanisms of quinolone resistance. Determination of chromosomal mutations at QRDRs of topoisomerase genes and PMQR genes was performed by PCR followed by direct sequencing. Boiled DNA template of Salmonella Typhi isolates for PCR were prepared by lysing the bacteria at 100 C and collecting the supernatant following centrifugation (10 000 g). The QRDRs of DNA gyrase (gyrA, gyrB) and topoisomerase IV (parC, parE) genes were amplified using published primers (Parry et al., 2010) . The PMQR genes, qnr (qnrA, qnrB, qnrD, qnrS) , aac(6¢)-Ib-cr and qepA, were determined following methods described by Accou-Demartin et al. (2011) . PCR amplicons were visualized on 1.5 % agarose gels after staining with GelRed nucleic acid gel stain (Biotium). Direct sequencing of the purified PCR products was performed by using a 3730 DNA Analyzer (Applied Biosystems). Sequence analysis was done online using the Clark et al. (2009) . For the zone size breakpoints, the following acceptable limits were used: !90 % for CA, 3 % for VMEs, 3 % for MEs and 7 % for mEs (Clark et al., 2009 ). 
RESULTS

Antimicrobial susceptibility testing
The scatter plots of inhibition zone diameters and MICs of nalidixic acid, ciprofloxacin, ofloxacin, levofloxacin and azithromycin for study isolates are shown in Figs 1, 2 and 3. To study the ciprofloxacin susceptibility trends of the isolates (n=146) over the 16-year period based on the MIC results, we divided the period into three phases: phase-I (1998 ( -2003 ( , n=35), phase-II (2004 ( -2008 ) and phase-III (2009-2013, n=71) (Fig. 4) . It was noticed that the trend of ciprofloxacin resistance increased significantly over the three phases (P<0.05). Among the isolates (n=146) with various ciprofloxacin susceptibility results, 32 (21.9 %) showed a MIC of 16 µg ml À1 for azithromycin (Fig. 5) .
QRDR mutations in quinolone-resistant isolates and association with FQ MICs
A total of 74 isolates of Salmonella Typhi were sequenced for detection of mutations in QRDRs of topoisomerase. A single mutation in gyrA (Ser83Phe, Ser83Tyr, Asp87Asn or Asp87Tyr) or in gyrB (Ser464Phe) was found in 53 isolates (Table 2) . Four isolates had double mutations, one in gyrA (Ser83Phe or Ser83Tyr) and the other either in parC (Glu84Gly or Glu84Lys) or in parE (Leu502Phe). Triple mutations were detected among 15 isolates, two in gyrA (Ser83Phe and Asp87Gly or Asp87Asn), and one in parC (Ser80Ile). PMQR genes were absent in the isolates.
The correlation of QRDR mutations and MICs of FQs in
Salmonella Typhi isolates is shown in Table 2 . Among 74 isolates, two nalidixic-acid-susceptible (MICs 2 µg ml À1 ) isolates had no mutation, but 69 nalidixic-acid-resistant (MICs !32 µg ml À1 ) isolates showed one or more mutations in QRDRs. Similarly, mutation was not found in ciprofloxacin-susceptible isolates (MICs 0.06 µg ml
À1
), whereas DCS isolates (MICs 0.125-0.5 µg ml À1 ) showed single or double mutations, and ciprofloxacin-resistant isolates (MICs !1.0 µg ml À1 ) showed double or triple mutations. Single or double mutations were also found in isolates with decreased susceptibility to ofloxacin and levofloxacin (MICs 0.25-1.0 µg ml À1 ), whereas triple mutations were detected in resistant isolates (MICs !2.0 µg ml
). Interestingly, a single mutation was noted in gyrB among nalidixicacid-susceptible isolates (n=3) with DCS ( Table 2) .
Correlation of DD and MIC breakpoints VME or ME of FQs was not observed in the study isolates following the published guidelines (Figs 1 and 2, Table 3 ). Among 23 (15.8 %) isolates with mEs of ciprofloxacin, 22 isolates were I by Etest and R by DD; on the other hand, one isolate was S by MIC result, but I by DD test. Among three (2.1 %) and four (2.7 %) isolates with mEs of ofloxacin and levofloxacin, respectively, all were S by Etest but I by DD test. The comparisons yielded a CA of 84.2 %, 97.9 % and 97.3 % for ciprofloxacin, ofloxacin and levofloxacin, respectively. The azithromycin zone diameter and MIC scatter plot showed five MEs (3.5 %) without any VME in the study isolates (Fig. 3, Table 3 ).
DISCUSSION
The primary purpose of determining clinical breakpoints of antimicrobials is to predict clinical outcomes of typhoid cases after treatment with the same antimicrobials. In this study, we performed nalidixic acid, ciprofloxacin, ofloxacin, levofloxacin and azithromycin susceptibility testing with 146 Salmonella Typhi clinical isolates from Kolkata during a 16-year (1998 to 2013) period by DD and Etest methods. The correlation of inhibition zone diameters with MIC breakpoints of the aforementioned antimicrobials was determined. In the case of typhoid, accurate detection of FQ susceptibility is important since treatment failures have been reported in Salmonella Typhi isolates having ciprofloxacin MICs as low as 0.125 µg ml
À1
. The study determined how well the FQ MICs correlated with the QRDR mutations in the study isolates (n=74).
An increasing trend of ciprofloxacin resistance as well as DCS among the study isolates was observed (Fig. 4) . This might explain the reason for treatment failure of typhoid cases with ciprofloxacin therapy over the last decade (Parry et al., 2010; Rahman et al., 2014) . Increasing isolation (40 %) of ciprofloxacin-resistant strains has been reported from Bangladesh also (Chiou et al., 2014) .
The error rates for the FQs were found to be acceptable according to the published guidelines (Clark et al., 2009) (84.2 %) were observed for ciprofloxacin, which corroborated earlier studies (Sjolund-Karlsson et al., 2014; Deak et al., 2015) . The high percentage of mEs in this study was due to the zone diameter limit of ciprofloxacin susceptibility (31 mm) recommended by CLSI (2012), which actually dissects the bacterial population as susceptible from non-susceptible without any evidence for resistance mechanisms at the molecular level.
The correlation between MICs of FQs and QRDR mutations showed reliability of MIC breakpoints to determine FQ susceptibility of Salmonella Typhi (Table 2 ). It was reported that Salmonella isolates with ciprofloxacin MIC of !0.125 µg ml À1 are likely to have at least one mutation as a component of the acquired resistance mechanism (Parry et al., 2010; Humphries et al., 2012; Sjolund-Karlsson et al., 2014; Deak et al., 2015) .
For economic reasons, most laboratories perform the DD method for antimicrobial susceptibility testing of any organism. Nalidixic acid could not be used as a surrogate marker for FQ susceptibility of Salmonella Typhi due to the emergence of nalidixic-acid-susceptible isolates with decreased susceptibility to ciprofloxacin (Parry et al., 2010) . Isolates (n=12) having similar phenotype of ciprofloxacin (range of MICs 0.125-0.5 µg ml
) and nalidixic acid (range of MICs 2-8 µg ml À1 ) were obtained in this study (Fig. 1) . A single mutation was found in the gyrB (Ser464-Phe) gene in nalidixic-acid-susceptible and DCS isolates, which has been reported previously (Accou-Demartin et al., 2011; Gupta et al., 2014) . DD breakpoints for ofloxacin and levofloxacin, as reported in an earlier study (Sjolund-Karlsson et al., 2014) , were applicable for the study isolates, confirming reliability of DD test results for detecting antimicrobial susceptibility. In this study, FQ resistance was mediated by mutation(s) in QRDRs of topoisomerase genes in the absence of PMQR determinants as reported previously (Chau et al., 2007; Menezes et al., 2011) . On the contrary, the emergence of PMQR genes like qnrB, qnrS and aac-6¢-Ib-cr was documented recently in Salmonella Typhi by other researchers (Geetha et al., 2014; SjolundKarlsson et al., 2015) . Although the PMQR mechanisms typically only confer decreased susceptibility to FQs, they disseminate rapidly due to their location on transmissible plasmids (Parry et al., 2010; Sjolund-Karlsson et al., 2015) .
Azithromycin has been used as an alternative drug for treatment of typhoid fever when Salmonella Typhi isolates have ciprofloxacin MIC !0.125 µg ml
, since there are no available data indicating whether high-dose ciprofloxacin monotherapy is efficacious in DCS isolates (Humphries et al., 2012) . This study showed that ME (3.5 %) of azithromycin exceeded the acceptable limit (Table 3) , whereas an earlier study reported VME (0.3 %) and ME (0.5 %) within acceptable limits (Parry et al., 2015) . We faced challenges in determining and interpreting the DD and Etest results for azithromycin due to the appearance of a double zone of inhibition, which was also noticed by earlier researchers (Parry et al., 2015) . Azithromycin resistance (MIC !32 µg ml
) among the study isolates (n=3) was not high (2.1 %), and it was noted that 21.9 % (n=32) of isolates showed MIC of 16 µg ml À1 (Fig. 5) . The isolates (n=35) with azithromycin MIC of 16 or !32 µg ml À1 were either DCS or ciprofloxacin-resistant, indicating ciprofloxacin therapy might not be effective for such isolates (Fig. 5) . Azithromycin resistance in Salmonella Typhi has been reported from other countries as well as India (Rai et al., 2012; Vlieghe et al., 2012; Hassing et al., 2014; Parry et al., 2015) . This may be due to prolonged use of azithromycin for typhoid treatment in the absence of standard guidelines for azithromycin susceptibility breakpoints of zone diameter and MIC. So far, the mechanism of azithromycin resistance in Salmonella Typhi has not been investigated, although mutation in the rlpD gene and presence of the mphA gene were reported in non-typhoidal Salmonella isolates showing azithromycin MICs of 64 to 128 µg ml À1 (Gunell et al., 2010) .
In conclusion, this study provides insight about the correlation of DD and MIC results of FQs and azithromycin for Salmonella Typhi Kolkata isolates over a 16-year period. MICs of FQs and mutations in QRDRs of topoisomerase genes showed reliability of MIC results for FQ susceptibility of Salmonella Typhi isolates. Based on the results of this study, ofloxacin (R, 15 mm; I, 16-24 mm and S, !25 mm) and levofloxacin (R, 18 mm; I, 19-27 mm and S, !28 mm) DD susceptibility breakpoints may be recommended currently which are not included in the CLSI guidelines. Azithromycin should be used judiciously in typhoid treatment with available CLSI guidelines. In view of the emerging FQ-and azithromycin-resistant Salmonella Typhi isolates, DD and MIC breakpoints of those antimicrobials should be revisited routinely along with the exploration of the molecular mechanism of resistance. (Clark et al., 2009 ).
